You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 28, 2014

Good Manufacturing Practices in Thailand

Informed Counsel

In Thailand, Good Manufacturing Practices (GMP) were first implemented in 1979 for local pharmaceutical manufacturers under the Drug Act 1967 (B.E. 2510). In 1984, the Thai Food and Drug Administration (FDA) campaigned seriously for the pharmaceutical industry, and ultimately managed to update pharmaceutical standards, with the first Guidelines to Good Manufacturing Practices being issued in 1987. Also, as a way to standardize pharmaceutical factories, the Thai FDA began to officially grant GMP Certificates in 1989. 

By 2001, Thailand had adopted GMP Guidelines based on internationally recognized World Health Organization (WHO) standards, and in the same year, the Thai FDA applied the new guidelines to all local manufacturers and overseas manufacturers that intended to export drugs into Thailand.

GMP Accreditation

As an ASEAN member, Thailand has implemented ASEAN GMP. In order to comply with the ASEAN Sectorial Mutual Recognition Arrangement (MRA), which was signed on April 10, 2009, Thailand must standardize its GMP guidelines to be in line with those of other ASEAN countries. In 2011, the Thai FDA issued GMP regulations and launched GMP Guidelines that complied with ASEAN GMP standards and the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S)—this provided guidance to local manufacturers and raised overall standards.

In order to maintain the same GMP standards for both local and overseas manufacturers, the Thai FDA launched the Notification of GMP Accreditation of Overseas Manufacturers on October 1, 2012. Under this Notification, overseas pharmaceutical manufacturers which had never before been recorded in the Drug Product Registry of Thailand needed to be accredited by the Thai FDA before Marketing Authorization (MA) could be obtained. Pharmaceutical import companies must also submit an application for GMP accreditation before or at the same time as drug registration.

Required Documents

The documents to be submitted to the Thai FDA for GMP accreditation are separated into two schemes, Non-PIC/S members and PIC/S members, based on the overseas manufacturer’s country. If the overseas manufacturer is from a country that is a PIC/S member, the documents for GMP accreditation will be the PIC/S member checklist. The amount of documents for a PIC/S member to submit is less than that for a Non-PIC/S member. The required documents include:

  1. A Plant Master File for PIC/S or Non-PIC/S members or Certified/Audited by PIC/S, complying with the requirements stated in the Notification of the Ministry of Public Health Re: Good Manufacturing Practices (GMP) and Requirements for Manufacturing of Modern Drugs in accordance with the Drug Act 2012 (B.E. 2555).
  2. The production details of the imported product, including details about the place and manufacturing area, production equipment involved in the manufacturing of each category of imported product, plant layout, and a flowchart and other relevant information indicating all manufacturing processes, including the premises.
  3. The latest GMP inspection report, issued by the authorized government agency of the country of origin or the International Certificate Organization (if applicable).
  4. A current Certificate of GMP, issued by the authorized government agency of the country of origin.

Under the four topics above, there are more than 100 documents to be submitted for PIC/S members and more than 200 documents to be submitted for Non-PIC/S members to the Thai FDA for GMP accreditation. All documents are reviewed by an FDA team of experts. Afterwards, all questions, requests, or suggestions will be sent to the applicant to answer and/or submit additional documents. A slide or video presentation of the manufacturer needs to be prepared to explain the manufacturing process, such as important zones of production, flow of production, etc.

The applicant is required to arrange for the translation of certain information which needs to be in Thai and submit it together with the English version. A company representative may be requested to meet with the subcommittee to explain and answer the expert team’s questions. A Corrective Action and Preventative Action (CAPA) proposal may need to be presented to the subcommittee for evaluation. In complex cases, an inspection at the site of manufacturing may be required by the Thai FDA.  

If manufacturing practices are considered to be GMP compliant and the CAPA proposal meets requirements, the Thai FDA will issue a GMP Certificate to an overseas manufacturer for the purpose of product registration. The same GMP Certificate may be used for other product registration applications if they have the same scope/type of manufacturing during the validity of the GMP Certificate, which is normally three years after the date of issuance. The GMP Certificate of an overseas manufacturer must therefore be renewed every three years.

Since its implementation in October 2012, only 10 manufacturers from PIC/S member countries have received GMP accreditation. Meanwhile, manufacturers from Non-PIC/S member countries are still pending accreditation. Due to limited staff and expert teams in the Thai FDA, along with the requirement to submit a large number of documents for manufacturers from Non-PIC/S member countries, it is more difficult for a Non-PIC/S member to be granted a GMP Certificate than it is for a PIC/S member.

Overseas manufacturers are not required to pay for GMP accreditation at any stage of the application.

Renewal and Ongoing Audits

As the GMP Certificate issued for an overseas manufacturer has to be renewed every three years, it seems that the Thai FDA is trying to control/audit all manufacturers with products registered in Thailand. Meanwhile, local manufacturers normally have to renew their GMP Certificates every two years.

The GMP accreditation regulation of overseas manufacturers does not, however, affect manufacturers with products that were submitted for drug registration before October 1, 2012, because the manufacturer’s name and address are available in the Thai FDA database. It would be possible to have them audited if product registration renewal was required. Unfortunately, there is no requirement in Thailand for product registration renewal every five years, unlike other countries in ASEAN such as Singapore, Malaysia, etc. Therefore, these overseas manufacturers are still awaiting audit by the Thai FDA. For the time being, there are no measures to manage the audit of these manufacturers. To complete the GMP system in Thailand, the Thai FDA has the burden to eliminate the gap between new and old overseas manufacturers. This leaves many observers wondering how best to control products from overseas manufacturers that have never been audited by the Thai FDA.

Comparisons among ASEAN Countries

Thailand is not currently a PIC/S member, so in order to ascend to the accepted list of ASEAN MRA, Thailand must develop its pharmaceutical GMP system to be on par with other ASEAN countries. This will reduce pharmaceutical trade barriers before the ASEAN Economic Community (AEC) is implemented in December 2015.         

ASEAN countries have country-specific regulations that differ due to the laws and regulations of each country. As in Thailand, GMP accreditation in Singapore came into effect on April 1, 2004, and all overseas manufacturers registering medicinal products in Singapore after that date have to meet the PIC/S GMP standard. Malaysia, too, now requires the GMP accreditation of manufacturers outside Malaysia to be taken into consideration before products are registered. Malaysia adopted the PIC/S Guide to GMP for medicinal products in 2002.

In Malaysia and Singapore, old manufacturers with products that have already been registered, but have never been audited, will be audited and inspected when Marketing Authorization is renewed. If the manufacturer does not pass inspection, Marketing Authorization will not be granted. For Cambodia, Lao PDR, Myanmar, Philippines, and Indonesia, however, the GMP accreditation requirements for new overseas manufacturers are not as stringent as those seen in Malaysia and Singapore. The development of GMP accreditation in those countries will likely grow in the future to be on par with other ASEAN countries.

RELATED INSIGHTS​ 

September 6, 2024
Addressing technical barriers to trade is a key priority for the Association of Southeast Asian Nations (ASEAN) as part of trade facilitation in achieving the single market and production base under the ASEAN Economic Community directive agreed in 2015. The region has been undertaking positive steps toward standard harmonization in ASEAN priority sectors, integrating and bringing about regulatory convergence by taking into account the diversities that exist in the ten ASEAN member states. Health supplements in ASEAN are under the responsibility of the Traditional Medicine and Health Supplement Product Working Group (TMHS PWG). One of the TMHS PWG’s outputs is the ASEAN Agreement on a Regulatory Framework for Health Supplements, which includes various technical requirements for health supplements that participating member states must adopt by adjusting their domestic regulations. The key ingredients of these health supplements are vitamins and minerals. While all ASEAN countries allow the use of vitamins and minerals in health supplements, the amounts allowed for use vary, depending on the nutritional requirements deemed appropriate by each country. Partly in response to these efforts for regional harmonization, there have been important changes to vitamin and mineral limits in certain ASEAN countries that are worth monitoring. Some of these are outlined below. Thailand In January 2024, the Thai Food and Drug Administration (TFDA) updated the Thai Recommended Daily Intake (Thai RDI) guidelines for the Thai population. Subsequently, the TFDA adjusted the vitamin and mineral limits in order to comply with the updated Thai RDI and to follow the ASEAN Agreement on a Regulatory Framework for Health Supplements. The TFDA’s adjustment of vitamin and mineral limits for use in food supplements came in Notification of the Ministry of Public Health (No. 448) B.E. 2566 (2023) Re: Food Supplements (No. 5), which was published in the Government Gazette on January
August 8, 2024
On July 19, 2024, Thailand’s Ministry of Public Health Notification No. 450 B.E.2567 (2024) came into effect after being published in the Government Gazette the day before. The notification introduces significant updates to the labeling requirements for prepackaged foods. This new regulation consolidates and updates Thailand’s rules for food labeling by repealing and replacing several previous notifications. The notification’s key changes and their implications for food businesses are identified below. 1. Clarified “Best Before” Definition The notification aligns the definition of “best before” with Codex standards. It now refers to the date marking the end of the period during which the food maintains its best quality under stated storage conditions. After this date, food quality may change, and the product cannot be marketed. 2. Updated Labeling Exceptions Certain foods are exempt from labeling requirements, with the latest list including: Foods sold directly to consumers by manufacturers who can provide product information. Unprocessed foods. Some fresh foods not sold directly to consumers. Prepackaged foods produced and sold for immediate consumption in food service settings. However, any of these exempt foods that have received food serial numbers must still have labels that comply with the notification. 3. Expiration Date and Best-Before Date Display The notification provides clearer language for displaying the expiration date and best-before date. If specific wording is required by other notifications, it must be followed. English equivalents are now permitted alongside Thai text. 4. Warning Displays Multiple applicable warnings can now be consolidated and displayed together, provided the complete message is included as specified. 5. Claims about Substances or Ingredients New guidelines have been established for making claims about food additives and ingredients. Claims should be factual, not deceptive, and provably not false. 6. Label Placement and Design Labels must be permanently affixed, proportionate to the packaging, and
August 8, 2024
Tilleke & Gibbins has contributed the Thailand chapter to the 2024 edition of Pharmaceutical Advertising from the International Comparative Legal Guides (ICLG) series published by Global Legal Group. This detailed guide offers an in-depth examination of pharmaceutical advertising laws and regulations in multiple jurisdictions around the globe. Each chapter of the guide, structured in a Q&A format, is organized into comprehensive sections covering various aspects of pharmaceutical advertising, including: General rules and codes of practice governing pharmaceutical advertising Required arrangements for ensuring compliance with advertising regulations Procedures for obtaining advertising approvals from regulatory authorities Penalties for non-compliance with advertising rules Guidelines for providing information prior to product authorization Requirements for advertisements directed at healthcare professionals Restrictions on the content of pharmaceutical advertisements The complete Thailand chapter is available as a PDF below. The Thailand chapter—and the full Pharmaceutical Advertising guide—are also freely available on the ICLG website.
July 31, 2024
On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025. Contents of Circular 12 The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements. Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation. Transitional Provisions Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning. Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission. From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.